| LncRNA Information | ||||||
|---|---|---|---|---|---|---|
| ID | EL1055 | Name | PCAT5 | Aliases | LINC01452; TPCAT-10-36067 | |
| Species | Homo sapiens | Chromosome | 10 | Start site | 35778302 | |
| End site | 35800920 | Chain | plus | Exon NO. | 3 | |
| Assembly | Ensembl Release 89 | Class | lincRNA | NCBI accession | NR_110138 | |
| Ensembl | ENSG00000280719 | Sequence | ||||
| Disease | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Disease | Method | Sample | Expression pattern | Dysfunction type | Description | PMID | Source | ||
| prostate cancer | RNA-seq, qPCR, knockdown etc. | cell lines (PC-3, 22Rv1) | up-regulated | interaction | In vitro validation of these alterations revealed a complex integrated phenotype affecting cell growth, migration, invasion, colony-forming potential and apoptosis. Our findings reveal a key molecular determinant of differences between PC and CRPC at the level of the transcriptome. Further, they establish PCAT5 as a novel oncogenic lncRNA in ERG-positive prostate cancers, with implications for defining CRPC biomarkers and new therapeutic interventions. | 26282172 | Lnc2Cancer | ||
| Interaction | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Interaction target | Level of interaction | Type of interaction | Description | PMID | Source | ||||
| ERG | RNA-TF | regulation | PCAT5 as a regulatory target for the transcription factor ERG, which is activated in approximately 50% of human prostate cancer. | 26282172 | |||||